Introduction
Sj€ ogren's syndrome (SS) is a systemic autoimmune disease characterized by a chronic inflammation of the exocrine glands. The broad clinical spectrum of the disease varies from a fully benign condition to a severe systemic disease potentially complicated by the development of mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas (NHL) [1] . Salivary gland involvement is the hallmark of the disease and is characterized by variable degrees of periductal inflammatory lesions; the composition of infiltrate also varies, with T cells predominating in mild infiltrates and B cells in severe ones, potentially leading to the formation of germinal centre (GC)-like structures [2] , that represent the progressive organization of foci into lymphoid-like structures. In secondary lymphoid organs, GCs are characterized by a light and dark zone segregation on haematoxylin and eosin (H&E) sections: the dark zone corresponds to the area of centroblast proliferation, whereas the light zone consists of centrocytes, T follicular helper cells and follicular dendritic cells (FDCs). In labial salivary gland specimens, the dark/light zone segregation is usually absent and GC-like structures are appreciable on H&E as areas of lighter staining, due to the presence of FDCs, within follicular areas [3] . The degree of glandular infiltration and its composition of the infiltrates correlate with the severity of the disease, and the detection of GC-like structures has a clinical relevance, being the presence of these structures linked to a more severe disease and MALT-NHL development [4, 5] ; however, despite this prognostic significance, they are inconsistently reported in the clinical practice [6] . Mechanisms underlying the variable degree of glandular infiltration in individual cases have not been extensively clarified; neither the urgent need for clinical biomarkers able to early identify patients with SS at risk to develop MALT-NHL is satisfied.
Recently, a growing interest has arisen for the role of the innate immune system in the pathogenesis of the disease and in determining the glandular infiltration; apoptosis of glandular tissue, dysregulation of inflammatory cytokines and toll-like receptor (TLR) activation have been described in both murine models of early disease and SS patients [7] [8] [9] . In recruiting inflammatory cells at the site of tissue damage, extracellular nucleotides act as chemotactic agents [10] ; from this perspective, the P2X7 receptor (P2X7R)-NLRP3 inflammasome platform seems to be fully involved in the pathogenesis of SS [11, 12] . In fact, the expression and the activity of P2X7R, an ATP-gated cation channel, and the inflammasome components NLRP3, ASC and caspase-1, are significantly higher in SS gland specimens with respect to non-SS sicca syndrome, leading to the release of mature IL-1b and IL-18, critically involved in the salivary gland inflammation [12] .
Besides their increased epithelial expression in the SS-related histopathological lesions [13] , both IL1b and IL-18 play a role in lymphomagenesis, orchestrating the formation of GC-like structures in salivary glands [12, [14] [15] [16] ; in this scenario, an intriguing working hypothesis can be proposed, that is to speculate that the complex P2X7R-inflammasome might represent the hallmark of different immuno-histopathological features and different complexity in the organization of the lymphocytic infiltrate in SS, being ultimately involved in the degenerative process leading to MALT-NHL development.
Methods

Study design
This prospective observational single-centre study was performed at the University of Pisa, a certified referral centre for SS in Italy. According to a standardized protocol, approved by the Ethics Committee of the University of Pisa, over the years, we have systematically sampled minor salivary gland biopsies from female subjects with suspected SS at the diagnosis, therefore collecting, in the years 2010-2013, 300 gland specimens: 147 from patients with a final diagnosis of SS and 153 from non-SS sicca controls. All the samples, frozen in liquid nitrogen, had been stored at À80°C; H&E stains from formalin-fixed and paraffin-embedded minor salivary gland tissues from the same patients had been also routinely collected. All participants have been regularly followed over the time. At the end of a median follow-up of 54 months, five of 147 patients undergoing the gland biopsy at the diagnosis developed a MALT-NHL in their major salivary glands.
For the purpose of this study, we retrieved from all the stored samples the minor salivary gland biopsies of these five SS-MALT-NHL subjects (all female) performed at the time of SS diagnosis. In addition, we progressively included in the analysis 45 biopsies from SS patients with different degree of severity in the organization of the lymphocytic infiltrate at baseline. In this group, 25 biopsies were characterized mainly by a T-cell infiltrate and did not present GC-like structures and 20 biopsies showed GC structures. As controls, we included 25 minor salivary gland biopsy samples from patients with suspected SS who, after the complete diagnostic workup, had been classified as affected by non-SS sicca syndrome.
Minor salivary gland samples were re-evaluated by an expert pathologist, not aware of final clinical diagnosis, who verified the presence of focal lymphocytic sialadenitis and of GC-like structures.
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from the diagnosis to the end of the follow-up. The following information was then available from subjects' clinical records: patients demographics, disease-related glandular and extra-glandular manifestations developed over the time, patient serological profile including antinuclear antibodies, anti-Ro/SSA, anti-La/SSB, rheumatoid factor, C3 and C4 levels and the presence of hypergammaglobulinemia.
Saliva sample collection and preparation
Unstimulated whole saliva was collected using the draining method according to the American and European Consensus Group criteria [17] , early in the morning after an overnight fast; subjects were requested to avoid drinking water or chewing gum or sucking sweets for the previous 12 h [18] . Samples, kept on ice whilst being immediately processed, were centrifuged at 21 000 g for 20 min at 4°C, thus removing debris and cells. Proteins were quantified using an RC DC protein assay (BioRad Laboratories, Segrate, Italy). Bovine serum albumin (BSA) was used as a reference standard.
Salivary gland samples: histopathology and immunohistochemistry
H&E sections from formalin-fixed, paraffinembedded labial salivary gland specimens were evaluated by the same pathologist. If a diagnosis of focal lymphocytic sialadenitis was made, the focus score (FS) was then determined according to the method of Greenspan and co-workers [19] . A focus was defined as an aggregate of ≥50 mononuclear cells (mostly lymphocytes) in a periductal localization. The FS was reported as the number of foci per 4 mm 2 of tissue, up to a maximum of 12 foci.
Gland biopsy specimens were also immunohistochemically stained with anti-CD20 and anti-CD3 antibodies (both from Ventana Med Systems, Tucson, AZ, USA) to assess the expression of B and T lymphocytes, respectively. The presence of GC-like structures was detected in H&E staining and using an additional immunohistochemical staining with anti-CD21 (Ventana) antibody, which is a marker of FDCs.
Lymphomonocyte isolation
Circulating mononuclear cells were isolated by density gradient centrifugation. Briefly, blood sample was collected in Vacutainers containing sodium heparinate, diluted (1 : 1) with sterile Dulbecco's phosphate-buffered saline (D-PBS), slowly laid onto warm Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA) and centrifuged at 400 g for 30 min at room temperature. To separate monocytes from lymphocytes, cell suspension (1 mL) was added to hyperosmotic Percoll solution (Sigma-Aldrich) in a final volume of 3 mL and centrifuged at 580 g for 15 min. Cells were added to D-PBS to a final volume of 15 mL and centrifuged at 350 g for 7 min, obtaining a monocyteenriched suspension. Platelets and dead cells were removed by overlaying 3 mL of iso-osmotic Percoll solution with 1 mL of the monocyte-enriched suspension and centrifuged at 350 g for 15 min; the supernatant was resuspended in D-PBS and centrifuged again at 350 g for 7 min, storing pellet at À80°C.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from salivary gland specimens and lymphocytes using the miRCURYRNA II kit (Exiqon, Vedbaek, Denmark). 1 lg RNA was reverse-transcribed in a reaction volume of 20 lL using the High Capacity cDNA Reverse Transcription kit (Life Technologies, Monza, Italy). Real-time PCR was performed in triplicate using an Eco RealTime System (Illumina Inc., San Diego, CA, USA) according to the standard protocol. Transcripts for P2X7R and inflammasome components and for P2X4R were evaluated using TaqMan Gene Expression assays (Applied Biosystems, Foster City, CA, USA), using the following probes: P2X7R, Hs00175721_ml; NRLP3, Hs00918082_ml; caspase-1, Hs00354832_ml; IL-18, Hs01038788_ml; IL-1b, Hs01555410_ml; P2X4R, Hs00602442_ml. Amplifications were normalized to GAPDH (Hs02758991_ g1), and gene expression was quantified according to DDCT calculation, where CT is the threshold cycle. The amount of the target gene, normalized to housekeeping and relative to the calibrator (total RNA from an healthy control), is given as 2 ÀDDCT .
Protein extraction from salivary glands
Three gland specimens from each study group were lysed with a specific buffer (NP40 Cell Lysis Buffer, Invitrogen, Carlsbad, CA, USA) and Protease Inhibitor Cocktail (Sigma-Aldrich) using a TissueLyser instrument (Qiagen, Hilden, Germany). Total protein content was measured by a Quick Start Bradford reagent (Bio-Rad, Hercules, CA, USA).
Western blotting
30 lg protein extracted from whole saliva or gland samples was diluted in sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) buffer and heated at 100°C for 5 min. Samples and molecular weight markers were electrophoresed on Any kD Mini-Protean TGX gels (Bio-Rad) and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). After blocking using 5% BSA in Tris-buffered saline and 0.05% Tween 20 (TTBS) for 1 h at room temperature, blots were washed three times in TTBS and incubated overnight with primary antibodies against caspase-1 (sc-515 Santa Cruz Biotechnology, Santa Cruz, CA, USA, diluted 1 : 100 and 06-503, Millipore, diluted 1 : 500), IL-1b diluted 1 : 500 (12242, Cell Signaling Technology, Danvers, MA, USA), IL-18 diluted 1 : 1000 (06-1115, Millipore) and b-actin diluted 1 : 1000 (sc-47778 Santa Cruz Biotechnology). Band detection was obtained by incubating blots with speciesspecific secondary antibodies (goat anti-rabbit for caspase-1, IL-18, AP307P, and goat anti-mouse for IL-1b and b-actin, AP308P, both from Chemicon International, Temecula, CA, USA), diluted 1 : 5000 for 1 h at room temperature, followed by enzymatic chemiluminescence.
To detect the mature isoform of caspase-1, not evident by using the Santa Cruz antibody, we performed membrane stripping (by StripAblot buffer, EMP100500, Euroclone, Pero, Italy) before using the Millipore antibody, specific for the 20-kDa mature isoform.
Immunostaining
A portion of minor salivary glands isolated from each patient was processed for immunostaining. After a short step of fixation (1 h at room temperature) with 4% paraformaldehyde in phosphate buffer pH 7.2, glands were cryoprotected (overnight at 4°C) in 30% sucrose and stored at À20°C in TissueTek until using. Transverse 12-lm-thick sections were cut with a cryostat microtome and processed for a standard immunostaining protocol. Briefly, after rinsing three times (10 min each) with D-PBS pH 7.4, gland sections were treated with 5% BSA/0.3% Triton X-100 in PBS for 1 h to block nonspecific binding; sections were left to react overnight at 4°C with different dilutions of specific primary antibody (1 : 100 P2X7R, APR-004 Alomone Labs, Jerusalem; 1 : 300 aquaporin V, sc-514022, Santa Cruz Biotechnology), anti-CD20 ready-to-use antibody solution (760-2531, Ventana) and anti-pan-keratin ready-to-use antibody solution (760-2595, Ventana). After 1-h incubation at room temperature with donkey anti-rabbit antibody 568-conjugated for P2X7R and anti-mouse 488-conjugated for aquaporin V and CD20, the slides, covered with an antifade mounting medium (ProLong Gold, Life Technologies), were acquired with a laser scanning confocal microscope (Leica TCS SP8, Milan, Italy). Immunoreactivity was quantified using ImageJ software: briefly, for each patient, three stacks of optical sections were analysed; after the transformation in gray scale images, threshold was set getting the average gray value of the background signal and immunoreactivity was measured as percentage of area of positive pixels. For 3D reconstruction, the LasX software (Leica) was used.
Statistical analysis
Data are expressed as mean AE SD for continuous variables and as absolute frequencies and percentages for nominal variables. Comparison was made using parametric Student's t-test and nonparametric Mann-Whitney U-test, as applicable, and ANOVA. Dichotomous variables were compared using contingency table analysis and Fisher's exact test. Spearman's rank correlation and Pearson's test were applied for detecting correlations between P2X7R/inflammasome components and different study parameters, including salivary gland focus score. In all statistical tests, a P < 0.05 was considered significant.
Results
The P2X7R-inflammasome complex in gland specimens from patients with SS and controls Table 1 summarizes demographic and clinical features of the subjects enrolled in the study. All the patients satisfied the 2002 AECG criteria [17] for the diagnosis of SS. Of the 45 samples, 25 were characterized mainly by a T-cell infiltrate and did not present GC-like structures (GCÀ), 15 were GC positive (GC+), and five minor salivary gland biopsies had been taken at the diagnosis from patients with SS who have developed an overt MALT-NHL over the follow-up. Finally, 25 biopsies had been obtained in patients with suspected SS who, after the complete diagnostic workup, were classified as affected by non-SS sicca syndrome and represent the controls. Figure S1 shows representative images of minor salivary gland samples from patients with and without GC-like structures and from controls with moderate nonspecific inflammatory infiltrate.
The first aim of the study was to measure the gene expression of the P2X7R-inflammasome-IL1b /IL-18 complex in gland specimens of a large cohort of patients with SS and non-SS. Data are shown in Table 2 : we were able to confirm our previously published data [12] , observing as P2X7R, and NLRP3 and caspase-1 were significantly more expressed in biopsies from patients with SS with respect to individuals carrying a non-SS sicca syndrome; accordingly, the former group was also characterized by a higher expression of IL-1b and IL-18. Moreover, patients with a higher focus score (FS ≥ 3) showed higher levels of caspase-1, IL-1b and IL-18: moderate to strong correlations were detected between the components of the P2X7R-NLRP3-inflammasome axis and the gland FS (Figure S2 ).
We then characterized this pro-inflammatory platform in the whole cohort according to the presence of specific autoantibodies. In patients with SS showing a positivity for anti-Ro/SSA, glandular P2X7R, NLRP3 caspase-1 and IL-1b were significantly higher than in seronegative patients (Fig. 1) . Interestingly, an association was also found between the expression of the inflammasome components and some of the traditional risk factors for lymphoma development, including low C4 levels and major salivary gland enlargement (SGE): SS patients with low levels of C4 and SS individuals presenting recurrent SGE showed a significantly higher expression of P2X7R, NLRP3, caspase-1, IL-18 and IL-1b (Table 3a and b, respectively). The P2X7R-inflammasome complex in gland specimens from patients with SS stratified according to the lymphoid organization and to MALT-NHL risk Our next step was to stratify baseline biopsies of patients according to their complexity. Figure 2 shows mRNA expression of the P2X7R-NLRP3-inflammasome components in these patient subgroups. P2X7R, NLRP3, caspase-1, IL-18 and IL-1b were strongly higher in patients with SS who had developed over the follow-up a MALT-NHL with respect to both GC+ patients, GCÀ patients and controls. IL-18 protein, strongly expressed in the context of myoepithelial lesion and in the neoplastic tissues of MALT-NHL individuals [20] , was more abundant also at the level of saliva respect to GC+ patients (Fig. 2) .
Protein expression of some members of the inflammasome platform (caspase-1, IL-1b and IL-18) in GC+ and GCÀ patients and in controls is reported in Figure S3 . Unfortunately, also due to the intrinsic characteristics of the disease, we did not have any further baseline gland specimen or saliva of patients with MALT-NHL to perform additional Western blots; however, the lack of significant difference between GC+ and GCÀ subjects is confirmed at the protein level for caspase-1 and IL-1b, and the correspondence between mRNA and protein in these groups might allow to speculate that the trend would have been the same for patients with MALT-NHL.
On this basis, we tested whether or not P2X7R protein was more represented in MALT-NHL gland samples. As shown in Fig. 3a , confocal microscopy analysis revealed a more pronounced expression of this receptor in these patients; Fig. 3b shows the quantification of P2X7R protein expression in all the gland biopsies. Noteworthy, the B cells' severe infiltrate in patients with MALT-NHL does not contribute to P2X7R expression, there being no immunoreactivity colocalization between P2X7R and CD20, an antibody that recognizes human B lymphocytes, even in the gland biopsy of the overt phase of the disease (Fig. 3a, lower panels) . This result suggests that the P2X7R signal in minor salivary glands of patients with SS derives mainly from the plasma membrane of the glands: as shown in Fig. 3c , P2X7R colocalizes in the basolateral, but not in the apical region, with aquaporin V, a plasma membrane marker of the acinar cells. Interestingly, P2X7R is also expressed in duct cells, as clearly visible in the enlarged detail (Fig. 3d) . By a three-dimensional confocal approach, we confirm in Figure S4 the subcellular localization of P2X7R at the level of plasma membrane.
Expression of P2X4R in MSGB from patients with SS stratified according to the lymphoid organization and to NHL risk P2X4R shares some characteristics with P2X7R that appear relevant in the modulation of the ATPrich tumour microenvironment, that is the P2X4/ P2X7/pannexin-1 signalling, which augments inflammasome activation in myeloid cells [21] ; therefore, we tested its expression in the glands of the whole study population. P2X4R was not differently expressed in patients with SS and controls (Fig. 4) , and we did not observe any association between P2X4R and the severity of the infiltrate composition in MSGBs (Fig. 4) . In the whole study population, gland P2X4R expression moderately correlated with the expression of P2X7R (r = 0.599, P = 0.002), NLRP3 (r = 0.431, P = 0.031) and IL-1b (r = 0.581, P = 0.002), but not with caspase-1 or IL-18 levels.
Expression of P2X7R and P2X4R in peripheral lymphocytes from patients with SS stratified according to the lymphoid organization and to NHL risk Lastly, to test whether the increased P2X 7 R expression would be specific of the glandular tissue of SS women with MALT-NHL or would be regarded as a systemic marker, we measured the P2X7R and P2X4R expression in peripheral lymphomonocytes of SS patients with MALT-NHL and in a subgroup of matched SS women who did not develop MALT-NHL over the follow-up. As shown in Table 4 , no difference was observed between the two groups (P = 0.55 and P = 0.68, respectively).
Discussion
Sj€ ogren's syndrome is associated with highly increased risk factors for the development of salivary gland MALT-NHL [19] , the most relevant complication of the disease, responsible for the excess of mortality in these patients with respect to the general population. Lymphomagenesis is a quite complex process, and over the years, a growing amount of research has been performed trying to identify valuable biomarkers able to select those patient candidates to lymphoproliferative complications [22, 23] . Several poor prognostic factors for MALT-NHL development have been recognized in literature including low C4, purpura, parotid gland swelling, CD4+ T-cell lymphocytopenia [9] ; lately, the presence of GC-like structures in the minor salivary glands of patients with SS has been related with the subsequent development of MALT-NHL [5] .
In this prospective observational study, through the investigation of the expression of the axis P2X7R-inflammasome in minor salivary gland biopsies of patients with SS and different severity in the lymphoid organization, we propose for the first time a putative biomarker likely able to predict the development of this severe complication, suggesting a novel, highly relevant clinical application of the bench determination of this pro-inflammatory platform.
We initially started to confirm in a larger group of patients our previous observations [12] , that is that the P2X7R-inflammasome complex was significantly more expressed in patients with SS with Table 3 Gene expression of the P2X7R-inflammasome components in salivary gland specimens of a group of patients with Sj€ ogren's syndrome according to C4 levels (panel a) and the presence of major salivary gland enlargement (SGE; panel b).
Low C4
(n = 9)
Normal C4
(n = 36) respect to controls, and even more in those patients with SS presenting a positivity for antiRo/SSA and higher focus score in the salivary gland biopsies. This observation supports the amount of data in favour of the potential involvement of innate immune response in the pathogenesis of SS [8, 24] , also suggesting that this inflammasome might account for the severity and the complexity of the infiltrate composition. Moreover, such increased expression, confirmed at the protein level by Western blot and immunohistochemistry, is extremely strong in people who will develop MALT-NHL years after receiving the diagnosis of SS. The use of different complementary techniques in this study, including confocal microscopy, allowed us to exactly localize P2X7R at the level of the plasma membrane, its natural cellular site, and to firmly demonstrate that the expression of P2X7R-inflammasome axis correlated with the complexity of the lymphoid infiltrate. Even more, CD20, that marks the abundant infiltrate of B lymphocytes, does not colocalize, unless sporadically, with P2X7R, indicating that the inflammasome activation is fully independent upon such infiltrate and represents an early, specific reaction of the epithelial cell itself, thus reinforcing the key role of 'epithelitis' in SS pathogenesis [25] .
Some authors have explored whether some polymorphisms of the P2X7R encoding gene might serve as biomarkers of lymphoproliferative diseases, but results have been contradictory [26] [27] [28] ; we do not have availability of DNA from our patients, but any SNP determination in such small number of individuals would be meaningless. Concerning the role of tissue/cell receptor expression, an involvement of the P2X7R-NLRP3 inflammasome axis in chronic lymphocytic leukaemia has been recently described [29] and a correlative expression of P2X7R and T complex polypeptide 1 (TCP-1), overexpressed in several forms of cancers and showing increased expression with advancing stage, was found in human lymphoma tissues [30] . Moreover, an overexpression of P2X7R in haematopoietic stem/progenitor cells results in the decrease in colony-forming ability in vitro and engraftment potential in vivo, suggesting that high-level P2X7R signalling might unfavourably affect the function of progenitor cells [31] . We show here, to our knowledge, the first prospective report documenting the quantitative determination of P2X7R in salivary gland biopsies (easily and routinely obtained in patients with Sj€ ogren's syndrome) can provide key information on the prognosis of these subjects; the long-term follow-up confers major strength to our study.
The lack of difference of P2X7R expression in peripheral monocytes might suggest two main explanations. The first could be that this biomarker is tissue specific; if so, we are showing here that its development occurs early in the natural history of the disease, being highly expressed in salivary gland specimens pertaining to the first biopsy performed in this cohort of patients to confirm the diagnostic suspect of SS. The second explanation would consider that, vice versa, lymphomonocytes have been collected years after the diagnosis, and we cannot exclude that immunomodulating therapies might have blunted a putatively different P2X7R expression between the two groups present at the onset of the disease. However, given the low prevalence of MALT-NHL in these patients with SS and the enormous amount of conditions that might influence the behaviour of circulating monocytes, the fact that our observation comes from the specific target tissue of SS, that is the salivary glands, should be regarded as an additional point of strength of the present work.
The significantly increased expression of the axis P2X7R-inflammasome in glandular biopsies taken at the diagnosis of the SS, years before the development of MALT-NHL, suggests that the axis P2X7R-inflammasome may represent a potential biomarker useful for selecting patients at risk for MALT-NHL, where we should concentrate major efforts in preventing the disease. Even more, the expression of P2X7R-inflammasome components significantly correlate with other traditional risk factors for MALT-NHL development, including low C4, and major salivary gland swelling; taken together, all these data allow us to speculate that the P2X7R-inflammasome axis might play a role in SS lymphomagenesis. This hypothesis can be somehow supported considering that IL-1b and IL-18, whose maturation and release (in other words, their biologic effects) are strictly dependent upon P2X7R-inflammasome activation, are crucial in orchestrating the gland infiltrates and the formation of GC-like structures [12, 16] . A specific pathogenetic role of the P2X7R-NLRP3 inflammasome platform seems to be supported also by the lack of difference in P2X4R expression between patients with SS developing or not developing MALT-NHL, suggesting that P2X4R-mediated inflammatory pathways, described already in other rheumatologic diseases [32, 33] , are not involved.
In this scenario, it is interesting to point out as, in patients with SS who developed MALT-NHL, the glandular expression of IL-18 was almost threefold higher than in controls or in the other patients with SS, reinforcing the hypothesis of a key role of this cytokine, via its increased P2X7R-mediated production, in the pathogenesis of lymphoproliferative malignancies; for example, in patients with T-cell acute leukaemia, IL-18 production is enhanced and it acts as a tumour cell proliferative factor [34] , and its serum levels are associated with the outcome of patients with diffuse large B-cell lymphoma [35] .
Conclusion
Our data reinforce the potential role of innate autoimmunity in SS glandular inflammation and P2X7 and lymphoma in Sjogren / C. Baldini et al.
damage, focusing the attention on the P2X7R-inflammasome axis as a novel potential pathway involved in both SS exocrinopathy and lymphomagenesis. Pending the confirmation of this preliminary observation in larger cohorts of patients, P2X7R-inflammasome axis could represent an interesting biomarker for lymphomagenesis in SS, opening novel opportunities for the early diagnosis of lymphoproliferative complications and for the development of potential targeted therapies for the disease.
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